EFL1: A Potential Drug Target for Cancer and Other Diseases (G79631)

Target Name: EFL1

NCBI ID: G79631

EFL1

EFL1: A Potential Drug Target for Cancer and Other Diseases

EFL1 (SDS2) is a protein that is expressed in various tissues throughout the body, including the brain. It is a key regulator of the cell cycle, and is involved in the development and progression of many diseases, including cancer.

Recent studies have identified EFL1 as a potential drug target (or biomarker) for the treatment of various diseases, including cancer. One of the main reasons for its potential as a drug target is its involvement in the regulation of the cell cycle. The cell cycle is the process by which cells grow, divide, and replicate their genetic material. EFL1 is a key regulator of the cell cycle, and is involved in the distribution of nuclear chromosomes throughout the cell.

In cancer, the cell cycle is often out of control, leading to the rapid growth and division of cells. This can lead to the formation of tumors, which can be life-threatening. EFL1 has been shown to play a key role in the regulation of the cell cycle in cancer cells.

In addition to its involvement in the cell cycle, EFL1 has also been shown to be involved in the development and progression of many other diseases, including cancer. For example, EFL1 has been shown to be involved in the development of leukemia, a type of cancer that affects the blood cells.

EFL1 has also been shown to be involved in the development of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. These conditions are characterized by the progressive loss of brain cells, and are often associated with the development of full-blown mental disorders.

In addition to its involvement in the development of these diseases, EFL1 has also been shown to be involved in the regulation of the immune system. This is important because the immune system is one of the body's first lines of defense against infections and diseases. EFL1 has been shown to play a key role in the regulation of the immune system, and is involved in the development of autoimmune diseases.

Recent studies have also identified EFL1 as a potential drug target for the treatment of other conditions, including heart disease and diabetes. These conditions are characterized by the presence of abnormal levels of certain molecules in the body, which can lead to the development of diseases. EFL1 has been shown to play a key role in the regulation of these conditions, and may be a useful target for the treatment of these diseases.

In conclusion, EFL1 (SDS2) is a protein that is involved in the regulation of the cell cycle and the development and progression of many diseases, including cancer. Its potential as a drug target (or biomarker) makes it an attractive target for the development of new treatments for these diseases. Further research is needed to fully understand the role of EFL1 in the development and progression of these diseases, and to determine the most effective way to use it as a treatment.

Protein Name: Elongation Factor Like GTPase 1

Functions: Involved in the biogenesis of the 60S ribosomal subunit and translational activation of ribosomes. Together with SBDS, triggers the GTP-dependent release of EIF6 from 60S pre-ribosomes in the cytoplasm, thereby activating ribosomes for translation competence by allowing 80S ribosome assembly and facilitating EIF6 recycling to the nucleus, where it is required for 60S rRNA processing and nuclear export. Has low intrinsic GTPase activity. GTPase activity is increased by contact with 60S ribosome subunits

The "EFL1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about EFL1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets